ImmuNext granted Roche exclusive, worldwide rights to develop and commercialize V-region immunoglobulin-containing suppressor of T cell activation (VISTA) agonists. ImmuNext, which said the deal is fo...
BCIQ Target Profiles
V-region immunoglobulin-containing suppressor of T cell activation (VISTA)